A new generation of vaccines and boosters against SARS-CoV-2 may take a page from the anti-influenza playbook, with shots periodically tailored to target the most commonly circulating virus
The increasing prevalence of new coronavirus variants is raising questions about how well protected those who’ve already had their Covid-19 shots are against evolving forms of the SARS-CoV-2